Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b

Bibliography

• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentre, randomized, double- blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-67
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 2002;59:1496-1506
   PubMed Web of Science ®Google Scholar
• Pachner AR. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology 1997;49:647-50
   PubMed Web of Science ®Google Scholar
• Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-72
   PubMed Web of Science ®Google Scholar
• Cook SD, Quinless JR, Jotkowitz A, Beaton P. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 2001;57:1080-4
   PubMed Web of Science ®Google Scholar
• Vallittu AM, Halminen M, Peltoniemi J, et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 2002;58:1786-90
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003;60:634-9
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-43
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2007;68:977-84
   PubMed Web of Science ®Google Scholar
• Hartung HP, Polman C, Bertolotto A, et al. Neutralising antibodies to interferon beta in multiple sclerosis. Expert panel report. J Neurol 2007;254(7):827-37
   PubMed Web of Science ®Google Scholar
• IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-94
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91
   PubMed Web of Science ®Google Scholar
• Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology 2004;62:2031-7
   PubMed Web of Science ®Google Scholar
• Francis GS, Rice GP, Alsop JC, et al. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55
   PubMed Web of Science ®Google Scholar
• Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005;65:40-7
   PubMed Web of Science ®Google Scholar
• Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and a delayed impact on efficacy of interferon-beta. Mult Scler 2008;14:212-8
   PubMed Web of Science ®Google Scholar
• Boz C, Oger J, Gibbs E, Grossberg SE. Neurologists of the UBC MS Clinic. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 2007;13:1127-37
   PubMed Web of Science ®Google Scholar
• Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003;60:37-43
   PubMed Web of Science ®Google Scholar
• Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-38
   PubMed Web of Science ®Google Scholar
• Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-9
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-9
   PubMed Web of Science ®Google Scholar
• Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: the challenge of IFN-β therapy. Eur J Neurol 2007;14:850-9
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Malucchi S, Milano E, et al. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000;48:95-100
   PubMedGoogle Scholar
• Pozzilli C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis. J Neurol 2002;249:50-6
   PubMed Web of Science ®Google Scholar
• Patti F, Cataldi ML, Nicoletti F, et al. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:404-7
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002;58:314-7
   PubMed Web of Science ®Google Scholar
• Durelli L, Barbero P, Bergui M, et al. The OPTimization of interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders. J Neurol 2008;255:1315-23
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Files JG, Gray JL, Do LT, et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998;18:1019-24
   PubMed Web of Science ®Google Scholar
• Pungor E Jr, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998;18:1025-30
   PubMed Web of Science ®Google Scholar
• Whitley E, Ball J. Statistic review 4: sample size calculation. Crit Care 2002;6:335-41
   PubMed Web of Science ®Google Scholar
• Altman DG. How large a sample? In: Gore SM, Altman DG, editors, Statistics in Practice. London: British Medical Association, 1982
   Google Scholar
• Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med 1992;11:1825-39
   PubMed Web of Science ®Google Scholar
• Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health 1993;14:43-68
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S. Modern Epidemiology. Second edition. Philadelphia: Lippincott-Ravens Publishers, 1998
   Google Scholar
• Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 1998;19:209-11
   PubMedGoogle Scholar
• Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-3
   PubMed Web of Science ®Google Scholar
• Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994;93:424-8
   PubMed Web of Science ®Google Scholar
• Milella M, Antonelli G, Santantonio T, et al. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepatogastroenterology 1995;42:201-4
   PubMed Web of Science ®Google Scholar
• Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52
   PubMed Web of Science ®Google Scholar
• Khan O, Zabad R, Caon C, et al. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2002;16:563-78
   PubMed Web of Science ®Google Scholar
• O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology 2002;59(Suppl 3):S1-S33
   PubMed Web of Science ®Google Scholar
• Rio J, Nos C, Tintore M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-6
   PubMed Web of Science ®Google Scholar
• Chiu AW, Ehrmantraut M, Richert ND, et al. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging. Clin Exp Immunol 2007;150:61-7
   PubMed Web of Science ®Google Scholar
• Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997;48:1446-8
   PubMed Web of Science ®Google Scholar
• McFarland HF, Frank JA, Albert PS. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-66
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFN beta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67:1681-3
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Al-Sabbagh A, Bennett R, et al. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study. BMC Neurol 2008;8:11
   PubMedGoogle Scholar
• The PRISMS (Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis) Study Group; and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-b-1a in relapsing MS. Neurology 2001;56:1628-36
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Stam MM, Alsop J, Abdalla J. The PRISMS (Preventing of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study report on neutralizing antibodies up to year 6 of treatment [abstract]. Neurology 2003;60(Suppl 1):A482-3
   Google Scholar
• Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K. Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Mult Scler 2008;14:837-42
   PubMed Web of Science ®Google Scholar
• Farrel A, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler 2007;13:567-77
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990;12:1266-70
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Millonig A, Gneiss C, et al. High dose intravenous interferon-beta in MS patients with neutralizing antibodies (HINABS). A pilot study [abstract]. Neurology 2008;70:A272-3
   Google Scholar
• Oger J, Francis G, Chang P. Chang on behalf of the PRISMS Study Group. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: The PRISMS study. J Neurol Sci 2005;237:45-52
   PubMed Web of Science ®Google Scholar
• Brackmann HH, Lenk H, Scharrer I, et al. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999;5:203-6
   PubMed Web of Science ®Google Scholar
• Hay CR, Baglin TP, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK haemophilia centre doctors' organization (UKHCDO). Br J Haematol 2000;111:78-90
   PubMed Web of Science ®Google Scholar
• Kakavanos R, Turner CT, Hopwood JJ, et al. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003;361:1608-13
   PubMed Web of Science ®Google Scholar
• Ahn J, Feng X, Patel N, et al. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci 2004;9:1547-55
   PubMed Web of Science ®Google Scholar
• O'Connor P, Arnason B, Comi G, et al. Interferon beta-1b 500 mcg, Interferon beta-1b 250 mcg and Glatiramer Acetate: Primary Outcomes of the Betaferon®/Betaseron® efficacy yielding outcomes of a new dose study [abstract]. Neurology 2008;71:153
   Google Scholar